A premenopausal woman has ER-positive, HER2-negative breast cancer with one positive axillary node and an Oncotype DX recurrence score of 19. Which

Question

A premenopausal woman has ER-positive, HER2-negative breast cancer with one positive axillary node and an Oncotype DX recurrence score of 19. Which RxPONDER finding is relevant to adjuvant treatment discussion?

Accepted Answer

Premenopausal participants with scores 0–25 showed benefit from chemoendocrine treatment

Answer

The assay determines HER2 status as the preferred next management strategy

Answer

Only patients with scores above 40 were included as the preferred next step

Answer

Chemotherapy provided no benefit in any premenopausal subgroup as the next step

Answer

The trial studied node-negative disease only as the preferred next management strategy

RxPONDER — SCE Medical Oncology MCQ

A premenopausal woman has ER-positive, HER2-negative breast cancer with one positive axillary node and an Oncotype DX recurrence score of 19. Which RxPONDER finding is relevant to adjuvant treatment discussion?